BioCentury | Oct 31, 2020
Finance

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Oct 27, 2020
Finance

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain By Jeff...
...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...2017 and its acquisition of antiviral play Pharmasset Inc....
...meager return thus far, the integration of Pharmasset...
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...of Phase IIa trial to treat HCV 11/21/11 - Gilead to acquire HCV drug developer Pharmasset Inc....
...deal disappointed investors, who had hoped for an acquisition with a large premium akin to Pharmasset Inc.’s...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...deal disappointed investors, who had hoped for an acquisition with a large premium akin to Pharmasset Inc.’s...
BioCentury | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

...Michael Sofia, were part of the management team at Pharmasset Inc. Gilead Sciences Inc. (NASDAQ:GILD) bought Pharmasset...
...III testing. Sovaldi became a critical piece of Gilead's massively profitable HCV franchise. McElhaugh was Pharmasset's...
BioCentury | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Abel De La Rosa and CMO Douglas Mayers. De La Rosa comes from HCV company Pharmasset Inc....
BioCentury | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Abel De La Rosa and CMO Douglas Mayers. De La Rosa comes from HCV company Pharmasset Inc....
Items per page:
1 - 10 of 409
BioCentury | Oct 31, 2020
Finance

Data Byte: at $1.9B valuation, Atea leads this week’s IPOs

...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Oct 27, 2020
Finance

With $1.8B valuation within reach, Sommadossi’s Atea readies ‘mega-IPO’

...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Oct 23, 2020
Deals

Roche in $350M deal with Sommadossi’s Atea for what it believes could be first oral COVID-19 antiviral

...Led by Idenix, Pharmasset co-founder, Atea is fresh off $215M round led by Bain By Jeff...
...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Sep 14, 2020
Deals

High takeout premium in $21B deal shows Gilead’s confidence in value of Immunomedics’ ADC

...2017 and its acquisition of antiviral play Pharmasset Inc....
...meager return thus far, the integration of Pharmasset...
BioCentury | May 21, 2020
Finance

With repurposed antiviral, Atea draws $215M as it preps Phase II COVID-19 trial

...Pharmaceuticals Inc., which Merck & Co. Inc. (NYSE:MRK) acquired for $3.9 billion in 2014; and Pharmasset Inc....
BioCentury | Oct 19, 2019
Finance

Achillion’s journey to $1 billion

...of Phase IIa trial to treat HCV 11/21/11 - Gilead to acquire HCV drug developer Pharmasset Inc....
...deal disappointed investors, who had hoped for an acquisition with a large premium akin to Pharmasset Inc.’s...
BioCentury | Oct 17, 2019
Company News

Deal streak continues for Alexion as Achillion’s story hits $930M high note

...deal disappointed investors, who had hoped for an acquisition with a large premium akin to Pharmasset Inc.’s...
BioCentury | Oct 4, 2019
Clinical News

Arbutus scuttles lead HBV capsid inhibitor program

...Michael Sofia, were part of the management team at Pharmasset Inc. Gilead Sciences Inc. (NASDAQ:GILD) bought Pharmasset...
...III testing. Sovaldi became a critical piece of Gilead's massively profitable HCV franchise. McElhaugh was Pharmasset's...
BioCentury | Nov 30, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Abel De La Rosa and CMO Douglas Mayers. De La Rosa comes from HCV company Pharmasset Inc....
BioCentury | Nov 27, 2018
Financial News

Pharmasset, Idenix vets lead HBV company Antios to $25M series A

...Abel De La Rosa and CMO Douglas Mayers. De La Rosa comes from HCV company Pharmasset Inc....
Items per page:
1 - 10 of 409